AFT PHARMACEUTICALS LIMITED (AFP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

AFP

AFP - AFT PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 1.53
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.05

22 May
2026

0.000

OPEN

$3.05

0.000

HIGH

$3.05

1

LOW

$3.05

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

Last ex-div: 18/06 - (franking ex-div 1.11c)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx12.5
DPS All xxxxxxxxxxxxxxx2.6
Sales/Revenue xxxxxxxxxxxxxxx226.3 M
Book Value Per Share xxxxxxxxxxxxxxx87.6
Net Operating Cash Flow xxxxxxxxxxxxxxx-10.4 M
Net Profit Margin xxxxxxxxxxxxxxx5.78 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx14.50 %
Return on Invested Capital xxxxxxxxxxxxxxx10.87 %
Return on Assets xxxxxxxxxxxxxxx7.81 %
Return on Equity xxxxxxxxxxxxxxx14.50 %
Return on Total Capital xxxxxxxxxxxxxxx17.57 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-12.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx10 M
Long Term Debt xxxxxxxxxxxxxxx35 M
Total Debt xxxxxxxxxxxxxxx45 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx9 M
Price To Book Value xxxxxxxxxxxxxxx3.20

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx8.7 M
Capex % of Sales xxxxxxxxxxxxxxx3.83 %
Cost of Goods Sold xxxxxxxxxxxxxxx128 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx76 M
Research & Development xxxxxxxxxxxxxxx10 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

25/05/2026

2

Overweight

-

-

Jarden retains an Overweight rating for AFT Pharmaceuticals with its target price increased to NZ$4.25 from NZ$4.20 following the FY26 results.

The company reported a 22% increase in revenue to NZ$255m alongside operating earnings of NZ$24.4m, outperforming both guidance and broker expectations.

Asian market disruptions from the previous period have normalised, and international operating losses narrowed as revenues scaled, though elevated inventories weighed on cash flows and net debt.

Management provided FY27 revenue guidance exceeding NZ$300m, supported by compounding home market growth and an expanded set of international distribution partnerships across more than 100 countries.

Modest operating earnings upgrades are applied to factor in the improved operating leverage, with the broker highlighting the underappreciated research and development portfolio as a key growth driver.

FORECAST
Jarden forecasts a full year FY26 dividend of 2.62 cents and EPS of 16.05 cents.
Jarden forecasts a full year FY27 dividend of 2.97 cents and EPS of 19.28 cents.
Access Extra Coverage Research History >

AFP STOCK CHART

FNArena News on AFP

1
Australian Broker Call *Extra* Edition – May 25, 2026

11:10 AM - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Apr 01, 2026

Apr 01 2026 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Aug 06, 2025

Aug 06 2025 - Daily Market Reports
4
Next Week At A Glance – 24-28 Jun 2024

Jun 21 2024 - Weekly Reports
5
Next Week At A Glance – 17-21 – Jun 2024

Jun 14 2024 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
2
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
3
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
4
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
5
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
6
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
7
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
8
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
9
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
10
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals